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ABSTRACT Infection with HIV-1 results in pronounced
immune suppression and susceptibility to opportunistic infec-
tions (OI). Reciprocally, OI augment HIV-1 replication. As we
have shown for Mycobacterium avium complex (MAC) and Pneu-
mocystis carinii, macrophages infected with opportunistic patho-
gens and within lymphoid tissues containing OI, exhibit striking
levels of viral replication. To explore potential underlying mech-
anisms for increased HIV-1 replication associated with coinfec-
tion, blood monocytes were exposed to MAC antigens (MAg) or
viable MAC and their levels of tumor necrosis factor a (TNFa)
and HIV-1 coreceptors monitored. MAC enhanced TNFa pro-
duction in vitro, consistent with its expression in coinfected
lymph nodes. Using a polyclonal antibody to the CCR5 corecep-
tor that mediates viral entry of macrophage tropic HIV-1, a
subset of unstimulated monocytes was shown to be CCR5-
positive by fluorescence-activated cell sorter analysis. After
stimulation with MAg or infection with MAC, CCR5 expression
was increased at both the mRNA level and on the cell surface.
Up-regulation of CCR5 by MAC was not paralleled by an
increase in the T cell tropic coreceptor, CXCR4. Increases in
NF-kB, TNFa, and CCR5 were consistent with the enhanced
production of HIV-1 in MAg-treated adherent macrophage
cultures as measured by HIV-1 p24 levels. Increased CCR5 was
also detected in coinfected lymph nodes as compared with tissues
with only HIV-1. The increased production of TNFa, together
with elevated expression of CCR5, provide potential mechanisms
for enhanced infection and replication of HIV-1 by macrophages
in OI-infected cells and tissues. Consequently, treating OI may
inhibit not only the OI-induced pathology, but also limit the viral
burden.
HIV-1 viremia occurs during acute infection when the virus is
replicating unchecked and again, late in disease when oppor-
tunistic infections (OI) are a universal problem. Common
pathogens such as human herpesvirus type 1 (HSV-1) and
Mycobacterium tuberculosis reportedly up-regulate HIV-1 pro-
duction in vitro (1, 2) and in vivo (3, 4). In HIV-1-infected
patients, clinical infections with M. tuberculosis, Giardia, My-
cobacterium avium complex (MAC), herpesvirus type 1, and
Pneumocystis carinii have all been shown to correlate with
reversible increases in levels of circulating HIV-1 (5–7). The
extensive viral replication identified in the tissues of such
patients provides compelling evidence that the OI influence
up-regulation of HIV-1 expression (8).
A potential source of the circulating virus, when only a limited
number of productively infected CD41 T cells can be detected in
the host, was recently revealed to involve cells of myeloid lineage.
Multinucleated giant cells (MNGC) and their mononuclear
(MNC) counterpart become a rich source of HIV-1 in tissues
coinfected with opportunistic pathogens (5, 8, 9). The produc-
tively infected cells, which were HIV-1 core protein (p24) positive
by immunohistochemistry and HIV-1-specific RNA-positive by
in situ hybridization (ISH), were identified as of monocytey
macrophage origin on the basis of their light and ultrastructural
morphology and pattern of immunophenotypic markers. The
presence of MAC within HIV-1 expressing MNC and MNGC
indicates their phagocytic capacity. In light of the recent classi-
fication of similar HIV-11 MNGC and MNC in hyperplastic
tonsils and adenoids as dendriticyLangerhans’ cells (DCyLC) (10,
11), we have focused on characterization of these key viral host
cells in OI-infected tissues. By multiple parameters, the predom-
inant productively infected cells in these coinfected tissues are of
monocyteymacrophage lineage, albeit distinct in that these cells
also express S100 protein and actin bundling protein p55 (fascin),
commonly considered to be associated with DCyLC (12). More-
over, we explored the cellular and molecular mechanisms
whereby MAC influences viral replication, identifying HIV-1
coreceptors and cytokines as candidate molecules. Recent evi-
dence has documented that, in addition to CD4, cellular viral
entry depends on the presence of G protein-coupled, seven
transmembrane spanning receptors belonging to the chemokine
receptor family (13–15). In what may be a key mechanism for
OI-enhanced susceptibility to HIV-1 infection, we provide evi-
dence that MAC augments monocyteymacrophage expression of
CCR5, a requisite coreceptor for HIV-1. Increased CCR5 ex-
pression together with up-regulation of tumor necrosis factor a
(TNFa), a reported promoter of HIV-1 replication (9, 16, 17), by
OI such as MAC may facilitate entry of HIV-1 and its replication
in target macrophages, contributing to the viremia that occurs in
late HIV-1 disease.
MATERIALS AND METHODS
Tissues, ISH, and Immunohistochemistry. Lymphoid tissue
biopsies obtained with consent from patients with AIDS-
defining OI and from HIV-1 seropositive subjects without
evidence of OI were fixed in 10% neutral buffered formalin,
embedded in paraffin and sectioned. Tissue sections were
processed for ISH by using 35S-labeled sense and antisense
probes for HIV-1 RNA (8) and TNFa (Molecular Histology,
Gaithersburg, MD). Deparaffinized sections were washed in
Tris buffered saline, preincubated for 10 min with blocking
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Abbreviations: OI, opportunistic infections; MAC, Mycobacterium
avium complex; MAg, MAC antigens; TNFa, tumor necrosis factor a
ISH, in situ hybridization; MNC, mononuclear cells; MNGC, multinu-
cleated giant cells; DCyLC, dendriticyLangerhans’ cells; IHC, immu-
nohistochemical; LAM, lipoarabinomannan; FACS, fluorescence-
activated cell sorter; TCID50, tissue culture 50% infective dose; LN,
lymph node.







































buffer, and incubated with primary antibodies: HAM56 (mac-
rophage-specific), CD68 (KP-1, macrophage-associated), S100
protein, p55 (actin-bundling protein), p24 UCHLyCD45RO
(T cells) (Dako), and CCR5 (18). Antibodies for a-1-
antitrypsin, a-1-antichymotrypsin and lysozyme were obtained
from Dako. The secondary antibodies were visualized with
New Fuchsin or peroxidase (8). For colocalization studies, ISH
was performed subsequent to immunohistochemical (IHC)
staining. For acid fast identification of M. avium, the tissues
were first hybridized and developed and Kinyoun’s stain was
applied to the emulsion-coated slides (8).
HIV-1 Infection of Monocytes. Human peripheral blood
cells, obtained by leukapheresis of normal volunteers (Depart-
ment of Transfusion Medicine, National Institutes of Health),
were density sedimented, and the monocytes in the mononu-
clear cell layer were purified by elutriation (19, 20). Monocytes
(1.5 3 106yml) in DMEM (BioWhittaker) with 2 mM L-
glutamine and 50 mgyml gentamicin were plated in 48-well
plates (Corning Costar). After adherence (4–6 hr at 37°C),
10% human AB2 serum (Department of Transfusion Medi-
cine) was added to the cultures. Cells were cultured 7–10 days
before being infected with HIV-1BaL (Advanced Biotechnol-
ogies, Columbia, MD) for 60 min at 37°C (21–23). Unbound
virus was removed by washing the cells with PBS and refeeding
with 0.5 ml DMEM containing 10% fetal calf serum, genta-
micin, and L-glutamine (complete medium). Every 3 to 4 days,
0.25 ml medium was removed for virus assay and replaced with
fresh complete medium. Supernatant p24 antigen was assayed
by using the p24 core profile ELISA kit from DuPont (23).
Assay of Virus Binding to Monocyte Surface. Approxi-
mately 5 3 106 monocytes in suspension or as adherent
monolayers were pretreated or not with MAg (10 mgyml,
overnight) or TNFa (1 ngyml, 4 hr). HIV-1BaL [1 3 103 or 4 3
103 tissue culture 50% infective dose (TCID50)yml] was added
for 30 min at 37°C in 1 ml DMEM (23). Cells were pelleted,
washed twice in PBS, and resuspended in 0.5% Triton X-100.
Virus in the lysate was quantified by p24 ELISA.
MAC and MAC Antigen (MAg) Preparation. M. avium was
grown under standard conditions (24) and added to adherent
macrophage monolayers at a ratio of 5:1. Mycobacterial antigen
(MAg) was made by freeze-thaw lysis of M. avium at 108
colony-forming unityml. After three cycles, the lysate was dis-
rupted by three 10-sec pulses of a probe sonicator (Heat Systems,
Farmingdale, NY). The protein concentration was determined by
bicinchoninic acid assay (25), adjusted to 2.5 mgyml, and added
to the cultures as indicated. M. avium cell wall glycolipid li-
poarabinomannan (LAM) was a generous gift from D. Chatter-
jee (Colorado State University, Fort Collins) (26).
Extraction of RNA and Northern Hybridization. Total cellular
RNA was extracted from nonadherent control or stimulated
monocytes by using the RNeasy minikit (Qiagen, Chatsworth,
CA). The RNA samples (5 mg) were subjected to formaldehyde-
agarose gel electrophoresis and transferred in 103 standard
saline citrate to Nytran membranes (Schleicher & Schuell). After
80°C for 1 hr, the membranes were prehybridized (4 hr at 42°C)
and hybridized with DNA probes: TNFa, CCR5, CXCR4 (14, 18,
27) (National Institutes of Health AIDS Research and Reference
Reagent Program), and glyceraldehyde-3-phosphate dehydroge-
nase (GIBCOyBRL). After washing, the hybridized filters were
exposed to phosphor screens and analyzed with a PhosphorIm-
ager (Molecular Dynamics).
Electrophoretic Mobility-Shift Assay. Adherent macrophages
were treated with MAg (1–25 mgyml) for 30 min and nuclear
extracts prepared (28). The NF-kB consensus oligonucleotide
probe (Promega) was end-labeled with [g32P] ATP by using T4
polynucleotide kinase. The binding reactions (25 ml) consisted of
incubating 3 mg of nuclear extract with reaction buffer (10 mM
Tris, pH 7.5y1 mM DTTy1 mM EDTAy0.08 mgyml salmon
sperm DNAy4% glycerol) adjusted to 0.1 M NaCl, with 0.05 pmol
of DNA probe for 30 min. The binding reactions were run on
nondenaturing 6% polyacrylamide gels (NOVEX, San Diego) in
.253 TrisyborateyEDTA buffer (25 mM Trisy25 mM boric
acidy0.5 mM EDTA, pH 8.3) that were dried and analyzed with
a PhosphorImager using IMAGEQUANT software (Molecular Dy-
namics).
Analysis of CCR5 Expression. Monocytes were incubated in
suspension with or without MAg, LAM, or lipopolysaccharide
(Escherichia coli 055:B5, Difco) at 37°C overnight and stained
with polyclonal anti-CCR5 generated against a synthetic peptide
derived from the N-terminal region of CCR5 at 10 mgyml (18) or
with anti-CXCR4 (PharMingen). Goat or donkey anti-rabbit or
goat anti-mouse IgG-conjugated with fluorescein isothiocyanate
(Jackson ImmunoResearch) was used at 1:100 as secondary
antibody for flow cytometry analysis using a FACScan (Becton
Dickinson). CD41 T lymphocytes prepared by elutriation were
stimulated with MAg (0.1–10 mgyml) in parallel, stained for
CCR5 and analyzed by fluorescence-activated cell sorter (FACS).
RESULTS
Enhanced HIV-1 Replication in Tissues and Cells Coin-
fected with MAC. MAC-infected lymph nodes from patients
with disseminated disease express large amounts of HIV-1-
specific RNA as detected by parallel bright- and dark-field
epif luorescence microscopy (Fig. 1 A and B) of ISH prepara-
tions (8). The cells producing the large quantities of HIV-1
were shown by ISH, combined with IHC, to be consistent with
Langhans’-type MNGC and their MNC counterpart and to be
coinfected with MAC (8). Scattered T lymphocytes, detected
by CD45RO staining, were also positive for HIV-1 by ISH. To
further characterize the population(s) of cells producing the
copious amounts of virus in these tissues, we assessed addi-
tional phenotypic markers. Unexpectedly, MAC-infected and
uninfected HIV-11 MNC and MNGC variably expressed both
S100 and p55, markers traditionally associated with DCyLC
(Fig. 1 C and D) (29). Colocalization of p24 in cells expressing
FIG. 1. Characterization of HIV-11 cells. Tissues from patients
coinfected with MAC and HIV were hybridized with the antisense
probe for HIV RNA together with IHC as described (8). (A) Bright-
field and (B) dark-field images of the same field after ISH. (C)
Combined IHC for S100 and ISH for HIV RNA. (D) IHC staining for
p55. (E) Colocalization of p24 antigen by IHC and HIV RNA by ISH.





































HIV-1 RNA by ISH confirmed their productive viral status
(Fig. 1E). Although expressing DCyLC markers, these HIV-
11, MAC-infected MNGC and MNC stained positively for the
myeloid, Golgi-associated markers, CD68, HAM56, lysozyme,
a-1-antitrypsin and a-1-antichymotrypsin (Fig. 2).
In addition to phenotypic markers consistent with macro-
phages, the HIV-1 host cells were highly phagocytic and lytic,
containing MAC within vacuoles and at various stages of
digestion within secondary lysosomes as detected by transmis-
sion electron microscopy (ref. 8, not shown). Also typical of
monocyteymacrophages, the cells had eccentric, moderately
pleomorphic nuclei, abundant Golgi, and complex plasma
membranes with stretches of subplasmalemmal linear densities
and many pinocytic vesicles. Neither Birbeck granules nor long
delicate ‘‘dendrite’’-like processes associated with DCyLC
were evident. Thus, by multiple morphologic and immuno-
phenotypic parameters, the cells expressing HIV-1 in the OI
tissues reflect a myeloid lineage.
Up-Regulation of CCR5 Expression in Monocytes by MAC.
Documentation of the impact of OI on viral replication,
particularly in macrophages, prompted exploration of a po-
tential mechanistic pathway that may contribute to the en-
hanced production of HIV-1. Because CCR5 expression is a
requisite for HIV-1 infection of macrophages, we explored a
potential link between MAC and CCR5. In response to MAg,
a 2- to 6-fold increase in CCR5 positive monocytes occurred
as determined by FACS analysis (Fig. 3), whereas MAg did not
enhance CXCR4, a coreceptor for T-tropic HIV-1 (Fig. 3A).
Based on the MAg dose response (Fig. 3B), 5–25 mgyml
provided optimal induction of cell surface CCR5, whereas
higher concentrations were ineffective andyor inhibited CCR5
expression. By comparison, lipopolysaccharide that activates
many monocyteymacrophage functions did not enhance CCR5
expression, as reported (30). To establish whether purified M.
avium LAM could independently trigger increased CCR5,
LAM at concentrations from 0.5–10 mgyml was added to
monocyte cultures for 18 hr and CCR5 expression monitored.
As evident in Fig. 3C, LAM at 5 mgyml induced a 3- to 4-fold
increase in FACS-detected monocyte CCR5. In contrast to
monocytes, T lymphocytes treated with MAg did not up-
regulate cell surface CCR5 expression (Fig. 3D).
By 30 min after exposure of the cells to MAg, mRNA
encoding CCR5 was significantly elevated, increased further at
3–5 hr, and remained above baseline at 22 hr (Fig. 4A).
CCR5-specific mRNA was also augmented in adherent mac-
rophages after actual infection with the mycobacteria (Fig.
4B). The rapidity of the MAg response and the recent evidence
for a NF-kB binding site in the CCR5 promoter (31) prompted
assessment of whether MAg influenced NF-kB activation.
Monocytes were cultured in the presence or absence of MAg
and NF-kB activation was monitored by electrophoretic mo-
bility-shift assay. NF-kB activation occurred within 30 min
after exposure to MAg in vitro (Fig. 4C), consistent with the
early increase in CCR5 mRNA.
MAg Augments HIV-1 Binding and Infection. Because MAg
augmented CCR5 expression, subsequent studies addressed
the impact of this receptor modulation on HIV-1 binding
andyor infection. Adherent macrophages or monocytes in
suspension were treated with MAg, exposed to HIV-1 for 30
min, washed repetitively, and lysed for quantification of cell
bound HIV-1 determined by p24 in the lysate (23). A nearly
2-fold increase in bound p24 was observed for adherent
macrophages that had been exposed to MAg (TCID50 5 1 3
103) (Fig. 5A). For unstimulated monocytes in suspension, no
detectable binding occurred at TCID50 5 1 3 103, although
p24 levels were detected in the MAg-treated cells (,50 pgyml,
limit of detection vs. 64 pgyml). When the concentration of
HIV-1 was increased 4-fold (TCID50 5 4 3 103), p24 binding
was detectable in control monocytes and elevated in MAg-
treated cells (Fig. 5B). These data are consistent with the
evidence that M. avium increases CCR5 to facilitate HIV-1
binding, and supports a role for MAC in increasing monocytey
macrophage vulnerability to HIV-1.
In the next series of experiments, macrophages were exposed
to MAg, HIV-1 was added to the cultures at increasing TCID50,
and HIV-1 production was monitored over time. Data are shown
beginning at day 11 when initial evidence of replication occurs
through day 18 when optimal p24 levels are routinely observed
(Fig. 5C). At the lowest viral inoculum, no p24 was detected on
FIG. 2. Phenotypic identification of MNC and MNGC in coin-
fected LN. IHC characterization of cells for lysozyme (A), CD68 (B)
and a1-antichymotrypsin (C). (D) Staining without the primary
antibodies was negative.
FIG. 3. M. avium enhances monocyte CCR5 expression. (A) Non-
adherent monocytes were exposed to MAg for 18–24 hr, and analyzed
for CCR5 or CXCR4 by FACS. B, C) Monocytes were stimulated with
increasing concentrations of (B) MAg (0.5–50 mgyml), lipopolysac-
charide (0.1–1 mgyml) or (C) LAM (0.5–10 mgyml) for 18 hr before
assessment of CCR5 expression. (D) CD41 T cells were exposed to
MAg (0.1–10 mgyml) for 18 hr before FACS analysis for CCR5. Data
represent mean 6 SE for three separate experiments.





































day 11, whereas at the highest viral concentration, significant p24
was detected only in cultures previously exposed to MAg. This
pattern persisted on day 14, when at the intermediate TCID50,
HIV-1 replication occurred only in MAg-treated cultures. At the
highest viral inoculum, HIV-1 production was evident in the
absence of MAg, but the levels were markedly increased with
MAg. By day 18, viral replication becomes maximal at TCID50 5
5 3 103, irrespective of MAg, and masking MAg-mediated
differences, although at the lower viral levels, MAg effectively
augmented p24 levels. The ability of MAg to increase CCR5
expression, thereby augmenting infection, especially at the lower
doses of viral challenge, appears to promote earlier and elevated
levels of HIV-1 expression.
Augmented TNFa Production in Vitro and in Coinfected
Tissues. The sustained ability of MAg to augment viral
production in macrophage cultures implicated a mechanism(s)
beyond increased bindingyinternalization via CCR5 receptors.
One potential mechanism considered was the ability of M.
avium to induce production of a regulatory cytokine(s) such as
TNFa (26). Based on the in vitro evidence for a role of TNFa
in regulating HIV-1 replication (16, 32), the tissues were
assayed for TNFa mRNA expression by ISH. As is evident in
Fig. 6, TNFa mRNA was detected in coinfected lymph node
(LN), in contrast to HIV-1-only infected tissues. Moreover,
exposure of monocytes in vitro to M. avium triggered a rapid
and transient increase in both TNFa mRNA (Fig. 6C) and
protein consistent with the presence of this cytokine in the
MAC-infected tissues of AIDS patients (Fig. 6B) and with
enhanced viral replication. Based on these data, we exposed
monocytes to TNFa, and determined that TNFa could also
augment CCR5 mRNA (not shown) and cell surface CCR5
expression (Fig. 6D) to increase HIV-1 binding as monitored
by p24 levels (Fig. 6E).
FIG. 4. M. avium augments CCR5 mRNA and NF-kB in mono-
cytes. (A) RNA isolated from control and MAg-stimulated monocytes
was probed for CCR5 and glyceraldehyde-3-phosphate dehydroge-
nase. RNA from U87 cells transfected with CCR5 or CXCR4 (pro-
vided by Carl Wild, BBI-Biotech Research Laboratories, Rockville,
MD), were positive and negative controls. (B) Adherent macrophages
were infected with viable M. avium (5:1) for 14 days and RNA probed
for CCR5 mRNA. (C) By electrophoretic mobility-shift assay, nuclear
extracts from MAg-stimulated (30 min) adherent macrophages were
analyzed by using a NF-kB consensus probe. Representative of three
experiments.
FIG. 5. M. avium increases HIV-1 binding and replication. Adher-
ent macrophages (A) or monocytes in suspension (B) were stimulated
with 25 mgyml MAg overnight, washed, and exposed to HIV-1 at
TCID50 5 1 3 103 (A) or TCID50 5 4 3 103 (B) for 30 min. The cells
were washed, lysed, and p24-monitored by ELISA. (C) Adherent
macrophages were pretreated with MAg (25 mgyml) and then infected
with increasing concentrations (1.25–5 3 103 TCID50) of HIV-1. After
1 hr, the unbound virus was washed away and the cells cultured for 18
days. Supernatants were collected at 3–5-day intervals and tested for
p24 by ELISA.
FIG. 6. MAg stimulates TNFa expression. LN from HIV-1-
infected (A) and HIV-1 plus MAC-infected (B) subjects were pro-
cessed for ISH with a TNFa antisense probe. Sense probes were
negative. (C) Monocytes were stimulated in vitro with MAg (25 mgyml)
and the isolated RNA probed for TNFa by Northern hybridization.
(D) Monocytes were exposed to TNFa (10 ngyml) overnight before
FACS analysis for CCR5. (E) Monocytes were treated with TNFa for
4 hrs and exposed to HIV-1 at TCID50 5 4 3 103 for 30 min. Cells were
washed, lysed, and assayed for p24 levels by ELISA.





































Increased CCR5 Expression in LN. Based on the augmen-
tation of TNFa and CCR5 HIV-1 coreceptor expression
induced by MAC in vitro, we reevaluated LN biopsies from
HIV-11 subjects with and without MAC infection for CD68
(macrophage specific) and CCR5. A marked increase in
CD681 macrophages was observed in the coinfected tissues as
compared with those only infected with HIV-1 (Fig. 7 A and
B), suggesting active recruitment. Parallel staining revealed
large numbers of intensely stained CCR5 positive cells in
coinfected tissues, in contrast to the virally-infected nodes
lacking MAC, in which paler staining of the lesser numbers of
macrophages made them difficult to detect (Fig. 7 C and D).
Background staining also appeared to be associated with the
intracellular microorganisms. Taken together, these observa-
tions reflect both an increase in the number of macrophages
and of CCR51 cells with apparent enhanced receptor density
in the coinfected tissues, and support our in vitro evidence
linking infection with MAC, up-regulation of CCR5, and
enhanced viral replication.
DISCUSSION
Activation of the immune system, whether by antigen, vacci-
nation, or infection has been associated with increased HIV-1
expression that is detectable both in the peripheral blood and
in tissues (reviewed in refs. 5, 8, and 33). Late in HIV-1 disease,
when the lymphoid tissues and peripheral blood are markedly
depleted of CD4 lymphocytes, not only is the level of circu-
lating HIV-1 maintained, but it is characteristically elevated
(17, 33). Our observations suggest that the source of the HIV-1
at this stage includes tissue macrophages. In our studies,
macrophages productively-infected with HIV-1 were present
in fungal, protozoan, bacterial, and virus-infected tissues (5, 8).
Striking production of HIV-1 was observed by tissue macro-
phages that were in mononuclear, and especially, multinucle-
ated forms. Because the HIV-1-producing macrophages, as
well as lymphocytes, need not be themselves infected by
pathogens, the up-regulation may occur via paracrine as well
as autocrine routes mediated by cytokines. And in fact, we
demonstrate that MAC up-regulates TNFa expression, which
reportedly can enhance HIV-1 replication (9, 16, 17, 32).
In systems where it has been analyzed, the mechanism of
TNFa up-regulation of HIV-1 appears to involve NF-kB (32,
34), and OI-induced TNFa may promote increased transcrip-
tion of viral long terminal repeat via this pathway (35, 36).
Moreover, we now demonstrate that, in addition to TNFa, M.
avium activates NF-kB to foster viral replication. Not only may
NF-kB promote viral replication, but the recent evidence for
NF-kB binding sites in the CCR5 promoter (31), provides an
intracellular pathway by which both TNFa and MAg influence
coreceptor expression and viral entry. In this regard, MAg
augmented NF-kB and CCR5 mRNA within minutes followed
by cell surface CCR5 expression.
MAg does not appear to influence T cell CCR5 expression,
nor is the response in macrophages triggered by all stimuli. For
example, lipopolysaccharide does not enhance, and may even
inhibit CCR5 on macrophages (Fig. 3B, ref. 30). As CCR5 is
an initial determinant of virus susceptibility (37, 38), these M.
avium mediated events likely promote HIV-1 entry as evi-
denced by increased HIV-1 binding. Associated with the
increases in CCR5 and TNFa, macrophages exposed to MAg
in culture exhibit a time- and dose-dependent enhancement of
HIV-1 infectionyreplication. By IHC, we also observed strik-
ing increases in CD681 macrophage numbers in HIV-1yMAC-
infected tissues, implicating active recruitment mechanisms,
including chemokine production (H.H.-D., unpublished ob-
servations), with amplification of the potential viral host
population. The increased numbers of CCR51 cells, also
expressing more CCR5, in the lymph nodes of patients coin-
fected with HIV-1 and MAC provide compelling evidence for
a parallel process in vivo. Although cellular activation and
cytokines such as TNFa may not play such an important role
in the absence of OI (Fig. 6, ref. 40), during coinfection, HIV-1
may be up-regulated by multiple mechanisms including both
cytokine and coreceptor levels.
Concerning the cellular origin of the virus in vivo, the
MAC-infected MNC and MNGC, regardless of HIV-1 p24 or
RNA levels, displayed a complex immunophenotype. In the
immunodeficient milieu of AIDS, these cells can phagocytize,
but do not effectively kill OI such as MAC, M. tuberculosis,
Cryptococcus neoformans, Coccidiodes immitis, and His-
toplasma capsulatum (5). Morphologically, these cells display
features typical of mononuclear phagocytic lineage as opposed
to DCyLC. Lacking Birbeck granules, the most specific mor-
phologic marker for DCyLC (41), the MNC and MNGC in the
MAC-infected specimens expressed an array of myeloid Golgi-
associated markers, as well as S100 protein and p55, generally
considered DCyLC markers (29, 41). As p55 is found on DC
and is up-regulated by Epstein–Barr virus in B cells (42),
perhaps infection with HIV-1 confounded by MAC provides
adequate impetus for its expression on myeloid cells. In that
both cell types have the same CD341, bone marrow-derived
progenitor cell (43), it is perhaps not surprising that they share
phenotypic markers under certain circumstances. Nonetheless,
although DC may be susceptible to infection by HIV-1, recent
studies conclude that active viral replication does not occur
efficiently in these cells (44, 45), thereby redirecting our focus
to the macrophages as the viral factories in the coinfected
tissues. Characterization of the relevant viral host cell popu-
lations is of importance in the development of targeted
therapies (9, 21, 22).
MAC represents the most common bacterial opportunist,
being diagnosed in up to 40% of AIDS patients (46), with autopsy
evidence indicating that the prevalence may be even higher. Our
FIG. 7. Increased CCR5 expression in coinfected LN. LN from
HIV-1-infected (A, C, and E) or HIV-1 plus MAC-infected (B, D, and
F) subjects were assessed by IHC for CD68 (macrophage marker) (A
and B) and CCR5 (C and D) expression. E and F represent parallel
staining without the primary antibodies.





































observations are consistent with the evidence and concern over
the deleterious side effects of immune activation or vaccination
of HIV-1-infected individuals, which can trigger nonspecific
stimulation of HIV-1 expression by cells otherwise producing
limited amounts of HIV-1 or which are latently infected (5, 8,
48–52). Productively-infected macrophages are infrequently
found in LN in the absence of OI; however, greater numbers of
cells with replication-competent integrated provirus are present
and are likely to be susceptible to immune stimulation-driven viral
replication provided by OI (8, 53). Long-lived HIV-1-infected
cells in the tissues are also considered major contributors to the
second-phase delayed decay of plasma viremia brought on by
antiretroviral treatment and may persist for at least 2–3 years
after treatment (53, 54). Thus, preventing and controlling im-
mune stimulation and OI, regardless of whether asymptomatic or
symptomatic, localized or disseminated, may continue to be an
important therapeutic strategy.
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